Genzyme's Ireland site expanded

Sanofi ($SNY) has expanded its Genzyme unit in Waterford, Ireland, 10 years after establishing it. CEO Christopher Viehbacher (photo) says was on hand with local officials at the inauguration of the $207 million campus expansion.

The site now boasts increased capacity for manufacturing operations, as well as additional development capability, lab facilities and administration offices. It currently employs 500, according to an announcement by economic development group IDA Ireland. The location has been home to oral dose manufacturing and packaging operations.

"Waterford is a strategic site within Genzyme," said Viehbacher, in the release. "Products from this location make a great difference in the lives of patients in more than 70 countries."

Sanofi offers "tremendous opportunities for growth for the Genzyme brand," added Genzyme senior VP for manufacturing ops Dominic Carolan.

- here's the release
- get more from RTE News

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.